XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholder Equity - USD ($)
$ in Millions
Total
Total stockholder equity
Common stock 
Capital surplus
(Accumulated deficit) Retained earnings
Treasury stock
Cumulative translation adjustment
Defined benefit postretirement plans
Cash flow hedging derivative
Non-controlling interest
Pension adjustments, tax benefit (expense) $ 0.3                  
Change in cumulative translation adjustment, tax expense (benefit) 1.5                  
Derivative financial instrument, tax expense (benefit) 0.1                  
Balance at beginning of period at Dec. 31, 2019 [1] 1,577.3 $ 1,519.1 $ 0.0 $ 2,116.8 $ (577.4) $ 0.0 $ 4.8 $ (24.0) $ (1.1) $ 58.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income (loss) (114.7) [2] (118.3)     (118.3)         3.6
Accretion - Series A Preferred Stock [3] (36.1) (36.1)   (36.1)            
Issuance of Common Stock in IPO, net of issuance costs 2,248.2 2,248.2   2,248.2            
Equity-based compensation plans 38.7 38.7   38.7            
Pension adjustments, net of tax expense (benefit) (1.0) (1.0)           (1.0)    
Change in cumulative translation adjustment, net of tax expense (benefit) (2.7) [2],[4] (3.7)         (3.7)     1.0
Derivative financial instruments, net of tax expense (benefit) 0.1 [2],[5] 0.1             0.1  
Preferred dividend (64.1) (64.1)   (64.1)            
Payment to non-controlling interest (6.8)                 (6.8)
Balance at end of period at Sep. 30, 2020 [1] 3,638.9 3,582.9 0.0 4,303.5 (695.7) 0.0 1.1 (25.0) (1.0) 56.0
Pension adjustments, tax benefit (expense) 0.3                  
Change in cumulative translation adjustment, tax expense (benefit) 2.4                  
Derivative financial instrument, tax expense (benefit) 0.2                  
Balance at beginning of period at Jun. 30, 2020 1,380.1 1,322.5 0.0 2,043.8 (679.4) 0.0 (16.2) (24.1) (1.6) 57.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income (loss) (14.3) [2] (16.3)     (16.3)         2.0
Issuance of Common Stock in IPO, net of issuance costs 2,248.2 2,248.2   2,248.2            
Equity-based compensation plans 11.5 11.5   11.5            
Pension adjustments, net of tax expense (benefit) (0.9) (0.9)           (0.9)    
Change in cumulative translation adjustment, net of tax expense (benefit) 19.4 [2],[4] 17.3         17.3     2.1
Derivative financial instruments, net of tax expense (benefit) 0.6 [2],[5] 0.6             0.6  
Preferred dividend 0.0 0.0   0.0            
Payment to non-controlling interest (5.7)                 (5.7)
Balance at end of period at Sep. 30, 2020 [1] 3,638.9 3,582.9 0.0 4,303.5 (695.7) 0.0 1.1 (25.0) (1.0) 56.0
Pension adjustments, tax benefit (expense) (0.2)                  
Change in cumulative translation adjustment, tax expense (benefit) 1.7                  
Derivative financial instrument, tax expense (benefit) 0.2                  
Balance at beginning of period at Dec. 31, 2020 [1] 3,583.9 3,525.6 0.0 4,310.1 (693.9) 0.0 30.1 (120.3) (0.4) 58.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income (loss) (55.9) (60.1)     (60.1)         4.2
Shares issued for Bisnode acquisition 158.9 158.9   158.9            
Equity-based compensation plans 21.7 21.7   22.0   (0.3)        
Pension adjustments, net of tax expense (benefit) 1.2 1.2           1.2    
Change in cumulative translation adjustment, net of tax expense (benefit) (63.2) [4] (64.8)         (64.8)     1.6
Derivative financial instruments, net of tax expense (benefit) 0.7 [5] 0.7             0.7  
Payment to non-controlling interest (2.0)                 (2.0)
Balance at end of period at Sep. 30, 2021 3,645.3 3,583.2 0.0 4,491.0 (754.0) (0.3) (34.7) (119.1) 0.3 62.1
Pension adjustments, tax benefit (expense) (0.1)                  
Change in cumulative translation adjustment, tax expense (benefit) (1.3)                  
Derivative financial instrument, tax expense (benefit) (0.1)                  
Balance at beginning of period at Jun. 30, 2021 3,648.6 3,587.9 0.0 4,482.3 (770.6) (0.3) (4.4) (119.5) 0.4 60.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income (loss) 18.2 16.6     16.6         1.6
Equity-based compensation plans 8.7 8.7   8.7   0.0        
Pension adjustments, net of tax expense (benefit) 0.4 0.4           0.4    
Change in cumulative translation adjustment, net of tax expense (benefit) (30.3) [4] (30.3)         (30.3)     0.0
Derivative financial instruments, net of tax expense (benefit) (0.1) [5] (0.1)             (0.1)  
Payment to non-controlling interest (0.2)                 (0.2)
Balance at end of period at Sep. 30, 2021 $ 3,645.3 $ 3,583.2 $ 0.0 $ 4,491.0 $ (754.0) $ (0.3) $ (34.7) $ (119.1) $ 0.3 $ 62.1
[1] See discussion in Note 1 - Basis of Presentation for further detail regarding the elimination of the International lag reporting.
[2] See discussion in Note 1 - Basis of Presentation for further detail regarding the elimination of the International lag reporting.
[3] Related to Series A Preferred Stock which was fully redeemed in July 2020. See detail discussion in the consolidated financial statements for the year ended December 31, 2020, included in our Annual Report on Form 10-K and filed with the Securities and Exchange Commission ("SEC") on February 25, 2021.
[4] Tax Expense (Benefit) of $(1.3) million and $2.4 million for the three months ended September 30, 2021 and 2020, respectively. Tax Expense (Benefit) of $1.7 million and $1.5 million for the nine months ended September 30, 2021 and 2020, respectively.
[5] Tax Expense (Benefit) of (0.1) million and $0.2 million for the three months ended September 30, 2021 and 2020, respectively. Tax Expense (Benefit) of $0.2 million and less than $0.1 million for the nine months ended September 30, 2021 and 2020, respectively.